Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 17, 2014 (12 years ago)

Gabapentin Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Tablet/Capsule Specifications: Complaints of empty capsules received.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Gabapentin Capsules, USP 300 mg, 100-count bottles, Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141; Manufactured by: Aurobindo Pharma Limited, Unit-VII (SEZ), Mahaboob Nagar (Dt), AP-509302, INDIA, NDC 16714-662-01, UPC 3 16714-662-01 5.

Affected NDC 16714-0662-01

Compare with the code on your package — it is the most precise check available.

Drug: Gabapentin Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Gabapentin
NDC 16714-0662
300 mg/1 Capsule
Oral
NorthStar Rx LLC Rx
Recalling firm
Aurobindo Pharma USA Inc
NDC code
16714-662-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0330-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Gabapentin recalls

See all
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0031-2026
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0030-2026
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 55154-3363-0 D-0508-2025
Class II · Moderate risk

Gabapentin Capsules

Defective container; blister packaging inadequately sealed.

Ongoing Packaging defect The Harvard Drug Group LLC NDC 0904-6665-61 D-0507-2025

Other recalls by Aurobindo Pharma USA Inc

All 2014 recalls
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025
Class II · Moderate risk

Nebivolol Tablets

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc D-0149-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025